Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.
about
Use of rodents as models of human diseasesRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondEmerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsNanoparticle ligand presentation for targeting solid tumorsGene delivery to Her-2+ breast cancer cells using a two-component delivery system to achieve specificityTransient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells.Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases.Biomaterials for mRNA delivery.Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy.Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.Systemic tumor-specific gene delivery.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.mRNA transcript therapy.In vivo reprogramming for tissue repair.Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape.Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity.Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells.Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.Suppression of mRNA Nanoparticle Transfection in Human Fibroblasts by Selected Interferon Inhibiting Small Molecule Compounds.A Safety Checkpoint to Eliminate Cancer Risk of the Immune Evasive Cells Derived from Human Embryonic Stem Cells.Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents.Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery.An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver.Gram-Scale Chemical Synthesis of Base-Modified Ribonucleoside-5'-O-Triphosphates.In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency.An Efficient Protection-Free One-Pot Chemical Synthesis of Modified Nucleoside-5'-Triphosphates.Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey.Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse.Engineering the Delivery System for CRISPR-Based Genome Editing.mRNA vaccines - a new era in vaccinology.The Influence of Extracellular RNA on Cell Behavior in Health, Disease and Regeneration.mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination.Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics.Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.
P2860
Q26822856-C422654B-4F8B-4DEA-88EC-52C3DAC76547Q26861563-102E152C-D01F-40CB-AF19-3940445A6EA9Q26996159-8129C63C-1A10-47E7-8999-0775345F67FCQ27009522-3C0EAA9A-8FF6-435A-B846-63F4208E8399Q34145147-C1C91562-3F53-44C1-89E4-FA2E78CD7AF5Q34459333-962F2E8F-60B9-4891-88EE-585032E7DF1AQ36216226-94EDEBD6-FCFC-4918-B504-11E3230E3B9BQ36271488-30795A64-FF62-4358-9ABC-9A271A7FCEF2Q36417403-1E908BA4-AE23-43D1-B288-39EDDCB461B4Q37330601-AF815987-B6BA-4D04-9A20-37CD2B2B1E5EQ37607987-0A7C1860-D2C8-460D-9FE4-2540F9CABD56Q38137609-C9A74DF6-CE70-4719-A046-C2AB0B3423C5Q38199151-FFDCD57C-6B7A-4CDB-950E-2AED191A9C2DQ38264088-88CDDAC2-2A10-4DEB-9F67-6AE4B7F03134Q38365611-F57D57E1-31EA-4B30-AAA5-92E28E926A48Q38825691-284091CA-43BA-4501-A97E-3F25F979C1D1Q38848999-15249B0F-D335-42C8-9C89-6FE79822B7BCQ38850538-035C78F1-1014-4472-A673-ADC95BC175F2Q38923727-F1D1B10B-9ABB-4A70-A4AA-9F7DBDB890E1Q39091854-83F331D7-DC30-48E2-8A2B-57FA3F131E05Q40113320-1B83788F-D031-44CE-A912-5669DC9CC0C5Q40379641-CA24BF32-EAC0-4233-BF8C-EBA968F2B9B6Q40445304-259379F9-A5DB-4205-A0FA-19CF6F4AE243Q41993335-5A4C7876-572A-4119-9222-8D389564AABBQ42276001-156093DD-F164-4DB8-BCC3-FCAFFD5D9CC0Q42565179-F4BC45A6-4499-4FF5-A6A3-1C02F0F0869DQ42642506-14C4AD7C-E6EC-4069-9910-D6E1EA343BABQ45862486-80787308-7B7B-4DE1-BD67-6682D42EA09DQ45876060-695ADF9C-044F-4975-97A3-4A669E00C83BQ45885769-E438897D-4E53-4CAA-A55A-87370B65E030Q46250879-7E522ADB-82C7-4CF6-9A2A-E563BEC4D14AQ47151105-A2F6F923-88DC-49AA-9917-AD73B1A842BCQ47198006-80A476E6-E55E-4759-BEB0-E4C5474ECB13Q47736893-01F11C97-D20C-4BF0-9A0B-4284644CFD80Q47931462-5E1417EE-1E12-47D9-B54D-EAA50600BF13Q49715007-BD6F7A20-4411-46AE-9F27-8EBEBBC734D7Q50454256-AD08D853-8C59-4433-8497-C03D8728D8E8Q52568128-9466B814-EED8-4B59-9F18-A87C55C5258FQ52626761-8E454DC4-2C16-4AA5-A806-CFADA18EE300Q52676614-758F5B05-C89D-47F3-B9F9-66B3663A28B8
P2860
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Systemic delivery of modified ...... targeted cancer gene therapy.
@ast
Systemic delivery of modified ...... targeted cancer gene therapy.
@en
type
label
Systemic delivery of modified ...... targeted cancer gene therapy.
@ast
Systemic delivery of modified ...... targeted cancer gene therapy.
@en
prefLabel
Systemic delivery of modified ...... targeted cancer gene therapy.
@ast
Systemic delivery of modified ...... targeted cancer gene therapy.
@en
P2093
P2860
P356
P1433
P1476
Systemic delivery of modified ...... targeted cancer gene therapy.
@en
P2093
Hsing-Hao Su
Leaf Huang
Pilar Blancafort
Yuhua Wang
P2860
P304
P356
10.1038/MT.2012.250
P577
2012-12-11T00:00:00Z